Search research articles
Contact Us
Filters
Showing results (171-180 of 225) with videos related to
Page
of 23
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 4, 2008
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer
Corey J Langer, Kenneth J O'Byrne, Mark A Socinski, et al.
JTO Clinical and Research Reports
|
April 21, 2025
Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy
Margaret Stalker, Suzanne L Walker, Emily Lebow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study
Stephen Leong, Roger B Cohen, Daniel L Gustafson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 22, 2023
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors
Cole Friedes, Michelle Iocolano, Sang Ho Lee, et al.
Journal of the National Cancer Institute
|
September 22, 2018
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck
Joshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 24, 2013
Impact of PET staging in limited-stage small-cell lung cancer
Eric P Xanthopoulos, Michael N Corradetti, Nandita Mitra, et al.
The Lancet. Oncology
|
November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Scott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 4, 2006
Small cell lung cancer clinical practice guidelines in oncology
Bruce E Johnson, Jeffrey Crawford, Robert J Downey, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2021
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
Steven F Powell, Delvys Rodríguez-Abreu, Corey J Langer, et al.
Clinical Lung Cancer
|
October 9, 2023
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression
Cole Friedes, Nikhil Yegya-Raman, Siqi Zhang, et al.
Page
of 23
Search research articles
Search
Showing results (171-180 of 225) with videos related to
Sort By:
Page
of 23
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 4, 2008
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer
Corey J Langer, Kenneth J O'Byrne, Mark A Socinski, et al.
JTO Clinical and Research Reports
|
April 21, 2025
Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy
Margaret Stalker, Suzanne L Walker, Emily Lebow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study
Stephen Leong, Roger B Cohen, Daniel L Gustafson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 22, 2023
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors
Cole Friedes, Michelle Iocolano, Sang Ho Lee, et al.
Journal of the National Cancer Institute
|
September 22, 2018
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck
Joshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 24, 2013
Impact of PET staging in limited-stage small-cell lung cancer
Eric P Xanthopoulos, Michael N Corradetti, Nandita Mitra, et al.
The Lancet. Oncology
|
November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Scott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 4, 2006
Small cell lung cancer clinical practice guidelines in oncology
Bruce E Johnson, Jeffrey Crawford, Robert J Downey, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2021
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
Steven F Powell, Delvys Rodríguez-Abreu, Corey J Langer, et al.
Clinical Lung Cancer
|
October 9, 2023
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression
Cole Friedes, Nikhil Yegya-Raman, Siqi Zhang, et al.
Page
of 23